Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Dec 3;18(6):773-4.
doi: 10.1016/j.cmet.2013.11.012.

Does reduced creatine synthesis protect against statin myopathy?

Kevin D Ballard  1 , Paul D Thompson
Affiliations
Comment

Does reduced creatine synthesis protect against statin myopathy?

Kevin D Ballard et al. Cell Metab. .

Abstract

Statins, widely used to lower cholesterol levels, cause myopathy in some patients. Mangravite et al. (2013) show that a single nucleotide polymorphism decreasing expression of glycine amidinotransferase (GATM), the enzyme regulating creatine biosynthesis, is associated with reduced statin myopathy. Whether reduced creatine production protects against statin myopathy remains to be determined.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Proposed Mechanism by Which Reduced GATM Activity Reduces Statin Myopathy Risk
Simvastatin reduced GATM transcriptional expression and this effect was associated with a reduced incidence of statin myopathy (Mangravite et al., 2013). Reduced intramuscular Cr may protect against statin-induced myopathy. GATM = glycine amidinotransferase; CP = creatine phosphate; Cr = creatine.
See this image and copyright information in PMC

Comment on

  • A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
    Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng Q, Rieder MJ, Chen YD, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, Collins R, Wilke RA, Nickerson DA, Stephens M, Krauss RM. Mangravite LM, et al. Nature. 2013 Oct 17;502(7471):377-80. doi: 10.1038/nature12508. Epub 2013 Aug 28. Nature. 2013. PMID: 23995691 Free PMC article.

References

    1. Edvardson S, Korman SH, Livne A, Shaag A, Saada A, Nalbandian R, Allouche-Arnon H, Gomori JM, Katz-Brull R. l-arginine:glycine amidinotransferase (AGAT) deficiency: clinical presentation and response to treatment in two patients with a novel mutation. Mol Genet Metab. 2010;101:228–232. - PubMed
    1. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337–343. - PubMed
    1. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008;359:789–799. - PubMed
    1. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013;502:377–380. - PMC - PubMed
    1. Mareedu RK, Modhia FM, Kanin EI, Linneman JG, Kitchner T, McCarty CA, Krauss RM, Wilke RA. Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev Cardiol. 2009;12:88–94. - PMC - PubMed

MeSH terms

Substances